Hims & Hers

forhims.com →

+19%

est. 2Y upside i

Healthcare

Telehealth platform providing online health and wellness services

Rank

#3024

Sector

Healthcare Providers & Services

Est. Liquidity

~1Y

Data Quality

Data: High

Hims & Hers offers a credible equity story anchored in 59% revenue growth, profitability, and 74% gross margins at a depressed 2.7x revenue multiple — meaningfully below where durable, profitable digital health platforms typically trade.

Last updated: May 5, 2026

Bull (28%)+85%

Revenue accelerates to ~$4.2B by end of 2027 as menopause expansion, new GLP-1 regulatory pathways, and AI personalization sustain 35-40% growth; market re-rates from 2.7x to ~4.5x revenue, implying a ~$19B market cap and ~85% appreciation from the current $6.25B baseline.

Base (37%)+20%

Revenue grows to ~$3.3B by end of 2027 at ~30% YoY but GLP-1 regulatory uncertainty and Amazon One Medical competition keep multiples compressed near 2.7x revenue; market cap reaches ~$7.5B, generating roughly 20% appreciation over the two-year horizon.

Bear (35%)-35%

FDA enforcement against compounded semaglutide removes a key growth driver and decelerates revenue growth to sub-15%; multiple compresses to ~1.5x revenue on a ~$2.8-3.0B top line, implying a market cap of ~$4.0-4.5B and a ~35% decline from current levels.

Est. time to liquidity~1.0 years

Preference Stack Risk

moderate

Funding Intensity

16%

The $1B convertible debt represents approximately 16% of the $6.25B current market cap; as a publicly traded NYSE-listed company (HIMS), this functions as dilution risk upon conversion rather than a traditional liquidation preference waterfall over common equity.

Dilution Risk

moderate

Convertible debt conversion plus ongoing RSU grants across 2,442 employees create meaningful share count expansion pressure that new-hire equity packages must grow through to generate real returns.

Secondary Liquidity

active

Hims & Hers is NYSE-listed (HIMS); RSUs are freely tradeable on public markets once vesting periods complete, with no liquidity event or secondary-market dependency required.

Questions to Ask at the Interview

Strategic questions based on Hims & Hers's data — designed to show you've done your homework.

  • 1

    “How is Hims & Hers differentiating against Amazon One Medical's weight management push, and what retention data shows subscribers aren't churning to Prime-bundled health services?”

  • 2

    “What fraction of 2025 revenue was generated from compounded semaglutide specifically, and what is the contingency revenue plan if FDA enforcement tightens the compounding pathway in 2026?”

  • 3

    “With $1B in convertible debt issued in May 2025, what is the conversion price and expected dilution impact, and how does management communicate the RSU value proposition to new hires in light of that overhang?”

Cluster Peers

Expected Upside

Hims & Hers
+19%
Thirty Madison
0%

Community

Valuation Sentiment

Our model estimates +19% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.